Both in Pharmaceuticals
Pfizer vs Bristol-Myers Squibb
Over the past year PFE returned +23.8% and BMY returned +35.6%; their daily moves had a correlation of 0.59.
PFE +23.8% BMY +35.6%Growth of $1, one year, split-adjusted
| Metric | PFE | BMY |
|---|---|---|
| Price | $30.52 | $62.48 |
| Market cap | $173.95B | $127.71B |
| Today | +1.90% | +1.78% |
| 1 month | +8.5% | +1.7% |
| 6 months | +15.9% | +7.3% |
| Year to date | +22.6% | +15.8% |
| 1 year | +25.6% | +46.7% |
| Revenue growth (YoY) | +2.6% | +5.7% |
| Gross margin | 72.8% | 71.3% |
| Net margin | −1.6% | 25.6% |
| P/E (TTM) | 40.2× | 13.8× |
| Price / sales | 2.7× | 2.6× |
| Net cash | -$51.49B | -$32.05B |
| Dividend yield | 5.64% | 4.03% |
| Volatility (60d) | 19.8% | 27.3% |
| Short % of float | 2.4% | 2.4% |
| Next earnings | Nov 3, 2026 | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).